Bayer AG and Thermo Fisher Scientific Inc. announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer?s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. The CDx will be developed using Thermo Fisher?s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated NGS platform that can deliver results on a patient?s tumor or liquid biopsy sample in as little as 24 hours.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.4 EUR | +1.88% | +4.08% | -18.53% |
Apr. 26 | Bayer CEO wins first AGM shareholder vote | RE |
Apr. 26 | BAYER SAYS INVESTORS WITH 91.69% OF EQUITY CAPITAL REPRESENTED A… | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
573.6 USD | +0.33% | +5.29% | 219B | ||
27.4 EUR | +1.88% | +4.08% | 28.74B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.53% | 28.74B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- BAYN Stock
- News Bayer AG
- Bayer AG and Thermo Fisher Scientific Inc. Collaborate to Increase Patient Access to Precision Cancer Medicines